Michele Patrizii
Overview
Explore the profile of Michele Patrizii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patrizii M, Bartucci M, Pine S, Sabaawy H
Front Oncol
. 2018 Feb;
8:23.
PMID: 29484285
Despite substantial effort and resources dedicated to drug discovery and development, new anticancer agents often fail in clinical trials. Among many reasons, the lack of reliable predictive preclinical cancer models...
2.
Haas T, Sciuto M, Brunetto L, Valvo C, Signore M, Fiori M, et al.
Cell Stem Cell
. 2017 Jun;
21(1):35-50.e9.
PMID: 28602620
Functionally relevant markers of glioblastoma stem-like cells (GSCs) have potential for therapeutic targeting to treat this aggressive disease. Here we used generation and screening of thousands of monoclonal antibodies to...
3.
Bartucci M, Hussein M, Huselid E, Flaherty K, Patrizii M, Laddha S, et al.
Target Oncol
. 2017 Jun;
12(4):449-462.
PMID: 28589491
Background: Hepatocellular carcinoma (HCC) represents one of the most lethal cancers worldwide due to therapy resistance and disease recurrence. Tumor relapse following treatment could be driven by the persistence of...
4.
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, et al.
Clin Cancer Res
. 2016 Jun;
22(24):6176-6191.
PMID: 27307599
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1...
5.
Maugeri-Sacca M, Bartucci M, Pagliuca A, Patrizii M, Signore M, De Maria R
Curr Pharm Des
. 2013 Oct;
20(24):3973-81.
PMID: 24138717
The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell lung cancer, compounds directed against oncogenic proteins offer novel therapeutic opportunities for a fraction of...
6.
Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, et al.
Stem Cells
. 2012 Jul;
30(9):1819-30.
PMID: 22753241
Tumor-initiating cells are responsible for tumor maintenance and relapse in solid and hematologic cancers. Although tumor-initiating cells were initially believed to be mainly quiescent, rapidly proliferating tumorigenic cells were found...
7.
Brambilla G, Patrizii M, De Filippis S, Bonazzi G, Mantovi P, Barchi D, et al.
Anal Chim Acta
. 2007 Mar;
586(1-2):326-9.
PMID: 17386731
Oxytetracycline (OXY) is a broad-range antimicrobial routinely used in pig production, at doses in the range of few g/kg of medicated feed, during the weaning period. It could persist at...